CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.34M, lower than 95% of all stocks globally
- PositionOperating margin is -10050.3%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.77BUSDvs all stocks (USD)
Revenue (TTM)
1.34MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0890xvs all stocks
52-Week Change
409.16%vs all stocks
Market Capitalization
5.77BUSDvs all stocks (USD)
Enterprise Value
4.66BUSDvs all stocks (USD)
Forward P/E
-22.70xvs Biotechnology peers
Price to Book (MRQ)
4.80xvs Biotechnology peers
Enterprise to Revenue
3.49Kxvs Biotechnology peers
Enterprise to EBITDA
-24.39xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-14.99%vs Biotechnology peers
Return on Equity (TTM)
-22.70%vs Biotechnology peers
Revenue (TTM)
1.34MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0320USDUpdated Jul 18, 2026Quarterly Revenue Growth
-60.20%vs Biotechnology peers
Gross Profit (TTM)
1.34MUSDvs all stocks (USD)
EBITDA (TTM)
-191.17MUSDvs all stocks (USD)
Net Income (TTM)
-173.66MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-60.19%vs Biotechnology peers
Operating Cash Flow (TTM)
-130.29MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-71.03MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.04MUSDFY2025 · Dec 31, 2025Operating Income
-177.93MUSDvs all stocks (USD)
Pre-tax Income
-162.34MUSDFY2025 · Dec 31, 2025Net Income
-162.34MUSDFY2025 · Dec 31, 2025EBIT
-177.93MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-177.96MUSDFY2025 · Dec 31, 2025Research & Development
145.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
34.33MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.12MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-162.34MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-122.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
51.25MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-162.34MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
428.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.79MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
755.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
11.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.93MUSDFY2025 · Dec 31, 2025Purchase of Investments
-435.01MUSDFY2025 · Dec 31, 2025Sale of Investments
312.39MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-122.62MUSDFY2025 · Dec 31, 2025Other Financing Charges
-364.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
271.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.58MSharesUpdated Jul 18, 2026Float Shares
54.60MSharesUpdated Jul 18, 2026Shares Short
9.53MSharesUpdated Jul 18, 2026Short Ratio
6.36daysvs all stocks
Short % of Shares Outstanding
20.07%vs all stocks
% Held by Insiders
0.13%vs all stocks
% Held by Institutions
121.23%vs all stocks
Total Cash (MRQ)
1.11BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
20.33USDUpdated Jul 18, 2026Total Debt (MRQ)
1.36MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0011xvs Biotechnology peers
Current Ratio (MRQ)
29.25xvs Biotechnology peers
Book Value per Share (MRQ)
22.01USDUpdated Jul 18, 2026Total Assets
530.92MUSDvs all stocks (USD)
Total Current Assets
409.44MUSDFY2025 · Dec 31, 2025Total Liabilities
37.52MUSDFY2025 · Dec 31, 2025Total Non-current Assets
121.48MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
6.79MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.73MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
51.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
353.21MUSDFY2025 · Dec 31, 2025Accounts Receivable
52.00KUSDFY2025 · Dec 31, 2025Accounts Payable
9.72MUSDFY2025 · Dec 31, 2025Short-term Debt
367.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
1.19MUSDFY2025 · Dec 31, 2025Long-term Debt
1.02MUSDFY2025 · Dec 31, 2025Common Stock (Book)
43.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-336.73MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
493.40MUSDvs all stocks (USD)
52-Week Low
18.08USDUpdated Jul 18, 202652-Week High
105.72USDUpdated Jul 18, 202652-Week Change
409.16%vs all stocks
Beta
0.0890xvs all stocks
50-Day MA
88.95USDUpdated Jul 18, 2026200-Day MA
63.19USDUpdated Jul 18, 2026Avg 10-Day Volume
1.04MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.40MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-4.23USDUpdated Jul 18, 2026Other Income / Expense
-523.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -10050.3%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -100.503Industry median: -0.24Industry P5: -32.91Peers compared: 197
Current ratio is 29.25×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 29.25Industry median: 5.50Industry P95: 22.03Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.34M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,336,000Global P5: 30,274,777.221
Market cap is $5.77B, above the global median of $1.15BNotable
Market cap (USD): 5,772,754,204Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule